Parkinson’s patients ‘owed’ more research into using cancer drug as treatment

News

Author: AdminPublished: 2 November 2015

Prep: Cook: Serves:

A small clinical trial showed that cancer drug Nilotinib may reverse late-stage Parkinson’s disease, potentially enabling participants to speak and walk again for the first time in years.

President and co-founder of The Cure Parkinson’s Trust, Tom Isaacs, has called for a close follow up of this small study to ensure that any opportunity for a breakthrough in the treatment of Parkinson’s is not missed.

Isaacs said: ‘Nilotinib is a case in point. When people with Parkinson’s volunteer for clinical trials and feel the type of marked improvements to their symptoms and wellbeing as those reported in this study, we owe it to them, and indeed everyone, to follow the results up as quickly and as rigorously as possible.”

Last Month

Next Month

Go Back

Share this story

Comments

Interviews

“Since being diagnosed with Parkinson’s, my world has expanded”

The latest in our monthly series profiling WPC2019 bloggers

‘Engagement platform’ lets carers log their work and receive rewards

Recognising and rewarding the work of carers via mobile platform

Aspiring Parkinson’s nurses urged to apply for “hands-on” summer school in Portugal

A unique opportunity to bring Parkinson’s nurses together

‘Dopamine-boosting’ BT13 molecule could be used to slow Parkinson’s

Researchers have discovered that a molecule called BT13 could have potential to treat Parkinson’s. The study, conducted by scientists from the University of Helsinki, Finland, found that mice injected with the BT13 molecule had an increase in dopamine levels in the brain. Their findings also suggested that the molecule could lead to a new drug treatment to protect the brain cells that produce dopamine. Dopamine helps coordinate movement, but people with Parkinson’s have normally lost between 70 and 80% of the brain cells that produce the neurotransmitter when they are diagnosed with the condition. Professor David Dexter, Deputy Director of Research at Parkinson’s UK – which co-funded the study – said: “People with Parkinson’s desperately need a new treatment that can stop the condition in its tracks, instead of just masking the symptoms. “More research is needed to turn BT13 into a treatment to be tested in clinical trials, to…

Students develop wearable device to track Parkinson’s tremors

A wearable device has been developed to monitor Parkinson’s tremors and their severity through the tracking of body movements. The device – Tremor Tracker – was created by two students, Julie Gaudin and Elizabeth Hummel, at Louisiana Tech University, US, as part of a design class project. The students designed an algorithm using data recorded from volunteer participants at Rock Steady, a boxing programme for people with Parkinson’s. They then applied the algorithm to a GENEActiv, a wrist-worn device that has been scientifically validated for clinical research. Hummel, co-creator of the Tremor Tracker, said: “Through supervised machine learning, the device predicts whether a patient’s tremors are parkinsonian or non-parkinsonian, as well as the severity of these tremors. A quantitative analysis of parkinsonian tremors provides a more detailed disease state.”

Can awakening dormant neurons reverse Parkinson’s motor symptoms?

Reawakening dormant neurons could help reverse Parkinson’s motor symptoms, researchers in South Korea have found. While Parkinson’s is typically believed to be caused by neuronal death, a new study – published in ‘Current Biology’ journal – suggests that dormant neurons could be another cause. After completing an animal test – which treated the subjects with two compounds that block dopamine-producing neurons from becoming dormant – the researchers found these neurons to be “awakened”, allowing them to resume dopamine production. The researchers hope that this will lead to a disease-modifying treatment, especially for people in the early stages of Parkinson’s. Hoon Ryu, a senior author of the study and researcher at KIST Brain Science Institute, South Korea, said: “This research refutes the common belief that there is no disease-modifying treatment for Parkinson’s due to its basis on neuronal cell death.”

All fields required

First name*
Last name*
Email address*
Enter Email Confirm Email
Country of residence*
About me*
- I have Parkinson's disease
- I am a partner / carer / family / friend of someone who has Parkinson's
- I am a healthcare professional with an interest in Parkinson's
- I work for a Parkinson's disease organisation
- Other
CAPTCHA
*
- By proceeding you agree to our
Email
This field is for validation purposes and should be left unchanged.

Parkinson’s patients ‘owed’ more research into using cancer drug as treatment

News

Author: AdminPublished: 2 November 2015

Prep: Cook: Serves:

Last Month

Next Month

Share this story

Comments

Interviews

“Since being diagnosed with Parkinson’s, my world has expanded”

Carers' Corner

‘Engagement platform’ lets carers log their work and receive rewards

PD in Practice

Aspiring Parkinson’s nurses urged to apply for “hands-on” summer school in Portugal

‘Dopamine-boosting’ BT13 molecule could be used to slow Parkinson’s

Students develop wearable device to track Parkinson’s tremors

Can awakening dormant neurons reverse Parkinson’s motor symptoms?

{title}

Subscribe

Parkinson’s patients ‘owed’ more research into using cancer drug as treatment

News

Author: AdminPublished: 2 November 2015

Prep: Cook: Serves:

Last Month

Next Month

Share this story

Comments

Related articles

Interviews

“Since being diagnosed with Parkinson’s, my world has expanded”

Carers' Corner

‘Engagement platform’ lets carers log their work and receive rewards

PD in Practice

Aspiring Parkinson’s nurses urged to apply for “hands-on” summer school in Portugal

‘Dopamine-boosting’ BT13 molecule could be used to slow Parkinson’s

Students develop wearable device to track Parkinson’s tremors

Can awakening dormant neurons reverse Parkinson’s motor symptoms?

{title}

Subscribe

Sign in